Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.

Bowen Chen,Linzhi Zhang,Jiamin Cheng,Tong Wu,Jin Lei,Xu Yang,Rongling Zhang,Rifaat Safadi,Yinyin Li,Tongguo Si,Yinying Lu

JOURNAL OF HEPATOLOGY（2022）

引用 0|浏览11

暂无评分

摘要

In our study, for off-label uHCC patients (Child-Pugh >7) with alcoholic cirrhosis, hyperammonemia, hypercholesterolemia, and estimated longer duration of treatment, the application of lenvatinib has to be cautious, which needs to be confirmed in future clinical trials.

查看译文

关键词

hepatic encephalopathy,hepatocellular carcinoma,lenvatinib,liver cirrhosis,sorafenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要